低门槛获取与监测对HIV暴露前预防的潜在风险与获益:模型研究
该建模研究模拟了亚特兰大GBMSM人群中诊所与OTC两种PrEP获取路径,发现OTC扩大覆盖可降低HIV发病率,但肾功能损害暴露、HBV再激活及耐药风险上升。敏感性分析显示起始时确认HIV阴性可大幅降低耐药且不削弱预防获益,定期肾功能监测可降低肾脏风险。
要点
- OTC PrEP扩大覆盖可降低HIV发病率,50%覆盖增幅避免15.4%感染。
- OTC PrEP伴随肾损害暴露升高、HBV再激活和耐药风险增加。
- 起始确认HIV阴性及定期肾功能监测可保留获益并降低风险。
核心结论
- OTC PrEP若将覆盖扩大至诊所外可产生人群水平HIV预防获益,但净公共卫生影响取决于保留安全功能的实施选择。
研究设计与样本
- 采用基于随机网络的HIV/STI传播模型,模拟亚特兰大GBMSM人群中诊所与OTC两种PrEP路径,并建模10年内PrEP覆盖增加10%-50%。
主要发现
- OTC PrEP在所有场景下降低HIV发病率,50%覆盖增加避免15.4%的HIV感染。
- 肾损害暴露从2.5%升至4.8%,HBV再激活达2.27/100人年,TDF/FTC耐药从0.68升至8.40事件/100例新发HIV感染。
关键数值与推荐
- 敏感性分析中,起始时确认HIV阴性状态使耐药降低>90%且不减少预防获益。
- 频繁肾功能监测可降低肾脏风险。
临床怎么用
- 实施OTC PrEP时应确保起始HIV检测以确认阴性状态,并保留定期肾功能监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pre-exposure prophylaxis (PrEP) prevents HIV acquisition, but its population-level impact is limited by access barriers. Low-barrier delivery of daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC), such as over-the-counter (OTC) availability, could improve access by eliminating clinic visits, though reduced monitoring may increase risks including drug resistance, renal toxicity, and hepatitis B virus (HBV) reactivation. We estimated the benefits and risks of OTC PrEP. METHODS: Using a stochastic network-based model of HIV/STI transmission among gay, bisexual, and other men who have sex with men (GBMSM) in Atlanta, we simulated 2 delivery pathways: clinic-based PrEP and OTC PrEP with simplified initiation and reduced monitoring. We modeled 10%-50% increases in PrEP coverage over 10 years. Outcomes included HIV infections averted, STI incidence, contraindicated PrEP use (GFR <60 mL/min/1.73 m2), HBV reactivations, and drug resistance. RESULTS: By expanding coverage, OTC PrEP reduced HIV incidence across all scenarios. A 50% coverage increase averted 15.4% of HIV infections. However, clinical risks increased: renal impairment exposure rose from 2.5% to 4.8%; HBV reactivations reached 2.27 per 100 person-years; and TDF/FTC resistance rose from 0.68 to 8.40 events per 100 incident HIV infections. In sensitivity analyses, confirming HIV-negative status at initiation reduced resistance by >90% without reducing prevention benefits, and frequent renal-monitoring reduced renal risk. CONCLUSIONS: OTC PrEP could produce population-level HIV prevention benefits if it expands coverage beyond clinic-based care. However, its net public health impact depends on implementation choices that preserve safety functions, particularly HIV testing at initiation and renal monitoring, without undermining access gains.
引用
- Le Guillou AV, Marcus JL, Krakower DS, et al. Potential Risks and Benefits of Low-barrier Access and Monitoring for HIV Pre-exposure Prophylaxis: A Modeling Study. J Infect Dis. 2026. PMID: 42467629. doi:10.1093/infdis/jiag369
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。